BIOFRONTERA AG/ADR (NASDAQ:BFRA) had its price target decreased by Lake Street Capital from $24.00 to $21.00 in a research note published on Wednesday, The Fly reports. Lake Street Capital currently has a buy rating on the stock.
Separately, Benchmark reiterated a buy rating on shares of BIOFRONTERA AG/ADR in a report on Tuesday, March 26th.
Shares of BFRA stock opened at $17.25 on Wednesday. The company has a fifty day moving average price of $16.73. The company has a debt-to-equity ratio of 1.56, a quick ratio of 3.38 and a current ratio of 3.84. BIOFRONTERA AG/ADR has a fifty-two week low of $11.04 and a fifty-two week high of $18.32.
About BIOFRONTERA AG/ADR
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.
Featured Article: How does a security become overbought?
Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.